Novo Nordisk fails to end US shareholder lawsuit over CagriSema clinical trial

NVO•2026-07-28

U.S. judge lets part of shareholder lawsuit proceed

July 28 (Reuters) - A U.S. judge said on Tuesday that Novo Nordisk NOVOb.CO must face part of a lawsuit accusing it of defrauding shareholders with misleading statements about a clinical trial for its weight loss and diabetes treatment CagriSema.

Novo Nordisk fails to end US shareholder lawsuit over CagriSema clinical trial

U.S. judge lets part of shareholder lawsuit proceed

Related News

NASDAQ Trade Halt <STKH.O> Volatility Trading Pause at 01:14 PM

Nasdaq Trade Halt <STFS.O> Volatility Trading Pause at 01:08 PM

Nasdaq trade halt continues SVA.O reason not available at 12:42 PM

First Community Corp EVP Fred Joseph Deutsch sells 10,000 common shares worth $345,150

Yemen's Houthis say they fired ballistic missiles at Saudi oil tanker in Red Sea